Plazinemdor (; developmental code name CAD-9303) is an NMDA receptor positive allosteric modulator which is or was under development for the treatment of schizophrenia. It is taken orally. The drug is intended for treatment of the negative and cognitive symptoms of schizophrenia. Plazinemdor was originated by Cadent Therapeutics and is or was under development by Novartis. As of April 2023, no recent development has been reported for schizophrenia.
See also List of investigational antipsychotics
References